broadens

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

2 weeks ago

Trex Broadens Western U.S. Reach Through Expansion With IWP

Strategic move reinforces Trex’s leadership position and supports ongoing growth in the Mountain RegionWINCHESTER, Va.--(BUSINESS WIRE)--Trex Company, Inc. (NYSE: TREX),…

3 months ago